Developer docs
API playgroundTry for free, no card

Search company profiles

Kincell Bio

Full company profile

uuid000092x

Namestring
Kincell Bio
Legal namestring
Kincell Bio
Websiteurl
kincellbio.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Kincell Bio is a U.S.-based cell therapy contract development and manufacturing organization (CDMO) founded in 2023 as a spinout of Inceptor Bio, headquartered in Gainesville, FL with a second facility in Research Triangle Park, NC. The company provides end-to-end CMC services to biotechnology and pharmaceutical companies developing engineered immune cell therapies, including process development, analytical development, GMP manufacturing, characterization and release testing, and tech transfer. Its modalities span CAR-T, CAR-NK, CAR-M, TCR-T, differentiated iPSC, and Treg programs across both autologous (one-batch, one-patient) and allogeneic (scalable, off-the-shelf) manufacturing models.

The platform is anchored in a two-site GMP manufacturing network with standardized process platforms enabling tech transfer from early-phase clinical supply in Gainesville to pivotal and commercial manufacturing in RTP. Kincell Bio sells directly to cell therapy sponsors through enterprise field sales, supported by content marketing, conference presence (CAR-TCR, Meeting on the Mesa, BIO, ASGCT, ISCT, CPHI), webinars, and LinkedIn thought leadership. Pricing is quote-based and negotiated per program; revenue is project-based with long-term, milestone-aligned contracts. The company has raised approximately $58 million in disclosed funding and is currently expanding the RTP facility to add two ISO 7 cleanrooms, additional QC, microbiology, and MSAT labs, expanded warehouse, and capacity for 100+ team members, with full operations targeted for Q3 2026. Leadership includes veterans from Catalent, Thermo Fisher, Brammer Bio, Resilience, Lyell, Fred Hutch, Pfizer, and Novartis, with Executive Chair Mark Bamforth having previously founded and exited three CDMOs.

Short descriptiontext

Kincell Bio is a U.S.-based cell therapy CDMO providing CMC development, process development, analytical services, and GMP manufacturing for autologous and allogeneic immune cell therapies (CAR-T, CAR-NK, TCR-T, iPSC, Treg) from facilities in Gainesville, FL and Research Triangle Park, NC.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy CDMO, contract manufacturing services, CMC development, GMP manufacturing, process development
Industry2 codes
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code1 code
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Cell Therapy CDMO Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Kincell Bio generates revenue through contract manufacturing and development services for cell therapy companies. Services include CMC roadmap development, process development, analytical development, GMP manufacturing, characterization and release testing, and tech transfer services. Revenue is project-based with long-term contracts typically aligned with client program milestones from early clinical through commercialization.

kincellbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Kincell Bio is a cell therapy Contract Development and Manufacturing Organization (CDMO) that provides integrated services across the full cell therapy product lifecycle for autologous and allogeneic programs including CAR-T, CAR-NK, CAR-M, TCR-T, iPSC, and Treg therapies. Services span CMC roadmap development, process and analytical development, GMP manufacturing, characterization and release testing, and tech transfer, delivered across two U.S. facilities in Gainesville, FL and Research Triangle Park, NC.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Supporting clients advancing from late-stage clinical CMC development through commercialization and post-approval lifecycle management for both autologous and allogeneic cell therapy programs
+1 more record
Product overview1 text field

Kincell Bio is a leading cell therapy CDMO (Contract Development and Manufacturing Organization) offering integrated services across the full cell therapy product lifecycle. The company's portfolio includes six core services: CMC Roadmap & Development, Early & Late Phase Process Development, Analytical Development & Methods, Clinical & Commercial GMP Manufacturing, Characterization & Release Testing, and Transfer In Playbook. These services support three development phases (Early-Phase Acceleration, Late-Phase Development, and Commercialization & Commercial Supply) and two therapy modalities (Autologous and Allogeneic Cell Therapies). Quality and regulatory support is provided through Quality Culture & Regulatory Support and PAI Readiness Program. The company operates two U.S. facilities (Gainesville, FL and Research Triangle Park, NC) providing end-to-end capabilities from concept through commercial supply.

Product and service13 records
1CMC Roadmap & Development
CategoryContract Development Services
Description

Strategic CMC roadmaps built for speed, rigor, and commercial success, helping innovators move cell therapies from concept to IND through structured CMC strategy, DoE-driven process development, and phase-appropriate analytics. Intended for cell therapy developers needing early-phase CMC planning.

2Early & Late Phase Process Development
CategoryContract Development Services
Description

Risk-based process development services from early feasibility through commercialization, integrating process optimization, control strategy strengthening, and scalable GMP execution. For cell therapy developers progressing from early feasibility to late-phase manufacturing.

3Analytical Development & Methods
CategoryAnalytical Services
Description

Phase-appropriate platform methods, custom-developed and validated methods, in-process testing, tracking, and trending to ensure safety, potency, and consistency. For cell therapy developers needing identity, potency, and safety analytical data.

4Clinical & Commercial GMP Manufacturing
CategoryContract Manufacturing Services
Description

Reliable, PAI-ready GMP manufacturing from early clinical through commercial supply, ensuring consistent, patient-ready cell therapy production across two U.S. facilities (Gainesville, FL and Research Triangle Park, NC). For cell therapy sponsors needing clinical and commercial GMP supply.

5Characterization & Release Testing
CategoryAnalytical Services
Description

Expert release testing and characterization ensuring safety and potency, building a foundation for quality and regulatory success through CQA-driven approaches and platform methods. For cell therapy developers requiring lot release and characterization support.

6Transfer In Playbook
CategoryContract Development Services
Description

Structured 8-point tech transfer playbook ensuring smooth program transitions using risk-based planning, cross-functional expertise, and phase-appropriate quality controls. For sponsors transferring cell therapy programs into Kincell's facilities.

7Early-Phase Acceleration
CategoryContract Development Services
Description

Risk-managed CMC roadmaps, DoE-driven process optimization, and phase-appropriate analytics balancing rapid IND readiness with long-term commercial strategy. For cell therapy sponsors preparing for IND filing and first-in-human studies.

8Late-Phase Development
CategoryContract Development Services
Description

Strengthened control strategies, process characterization, and comparability planning aligning analytical rigor, manufacturing scalability, and regulatory readiness for pivotal studies and BLA preparation. For sponsors advancing toward pivotal trials.

9Commercialization & Commercial Supply
CategoryContract Manufacturing Services
Description

Inspection-ready GMP operations, scalable manufacturing platforms, validated analytical control strategies, and supply chain resilience ensuring reliable, cost-conscious commercial supply. For sponsors of approved and late-stage cell therapies.

10Autologous Cell Therapy CDMO
CategoryContract Manufacturing Services
Description

Disciplined scale-out manufacturing for autologous therapies with one-batch, one-patient model, strict chain-of-identity controls, and scalable GMP production. For sponsors of patient-derived cell therapies such as CAR-T.

11Allogeneic Cell Therapy CDMO
CategoryContract Manufacturing Services
Description

Scalable allogeneic cell therapy manufacturing enabling off-the-shelf treatments with robust cell banking, scalable expansion platforms, and commercial-ready automation. For sponsors of donor-derived or renewable cell source therapies.

12Quality Culture & Regulatory Support
CategoryQuality & Regulatory Services
Description

Embedding quality and regulatory readiness into every phase of cell therapy development with integrated CMC, analytics, and quality systems for inspection-ready operations. For sponsors needing integrated quality and regulatory support across development and manufacturing.

13PAI Readiness Program
CategoryQuality & Regulatory Services
Description

PAI readiness built into everyday operations through regulatory mapping, phase-appropriate requirements, extensive operator training, data integrity, and analytical method readiness. For sponsors preparing for FDA pre-approval inspection.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

Kincell Bio announced a partnership with RegCell, a biotechnology company developing Treg cell therapies for autoimmune diseases. Under the partnership, Kincell provides CMC development and GMP manufacturing support to accelerate RegCell's lead Treg program toward clinical trials, including process transfer, scalable manufacturing development, and clinical material supply for IND-enabling activities. RegCell's platform is based on epigenetically reprogrammed regulatory T cells developed by co-founder Professor Shimon Sakaguchi, the 2025 Nobel Prize laureate in Physiology or Medicine.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

U.S.-based cell and gene therapy CDMO offering process development, GMP manufacturing, and analytical services across modalities including autologous and allogeneic therapies. Direct competitor for the same biotech customer base, with overlapping service lines and similar facility footprint scale.

TypeBroad incumbent
Description

One of the largest global CDMOs with a dedicated cell and gene therapy business acquired by Novo Holdings in 2024. Offers a broad portfolio that includes cell therapy manufacturing, viral vectors, and biologics; competes with Kincell for cell therapy contracts but as part of a much larger service portfolio.

TypeBroad incumbent
Description

Global CDMO leader with extensive cell and gene therapy manufacturing capacity, including autologous and allogeneic platforms. Competes with Kincell for commercial-scale cell therapy supply contracts and represents one of the most likely strategic acquirers or partners for emerging cell therapy CDMOs.

TypeBroad incumbent
Description

Large CRO/CDMO offering cell therapy manufacturing, viral vector production, and integrated discovery-to-commercial services. Competes with Kincell primarily through its Cell & Gene Therapy CDMO segment and brings significantly broader scientific services and global reach.

TypeDirect peer
Description

Cell and gene therapy manufacturing services arm of WuXi AppTec/WuXi Biologics, offering process development, viral vectors, and cell therapy manufacturing. Direct competitor with substantial scale, though geopolitical and biosecurity policy risks have complicated its U.S. market position, opening room for Kincell.

TypeBroad incumbent
Description

Global CDMO providing cell therapy, viral vector, and biologics manufacturing services with facilities in the U.S. and Europe. Competes with Kincell for cell therapy developers seeking integrated CMC and GMP services at commercial scale.

TypeEmerging player
Description

Cell therapy manufacturing technology company developing automated, closed-system Cell Shuttle platforms for autologous cell therapy production. Represents both a potential partner for Kincell's autologous work and a competitive threat if sponsors adopt in-house automated manufacturing.

TypeEmerging player
Description

U.S.-based cell and gene therapy CDMO offering viral vector, cell therapy, and analytical services from its Indianapolis facility. Comparable size and growth stage to Kincell, serving a similar early-to-mid-stage biotech customer base.

TypeEmerging player
Description

Emerging U.S. CDMO offering Portable CMC antibody and cell therapy process development and GMP services. Comparable scale and customer segment to Kincell; Kincell's Chief Commercial Officer previously launched Wheeler's Portable CMC service.

TypeEmerging player
Description

Cell and gene therapy CDMO offering viral vector and cell therapy manufacturing from a Texas facility. Comparable scale to Kincell with overlapping customer segments in early-to-mid-stage cell and gene therapy developers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kincell Bio

Cell Therapy CDMO Serviceskincellbio.com

Kincell Bio is a U.S.-based cell therapy CDMO providing CMC development, process development, analytical services, and GMP manufacturing for autologous and allogeneic immune cell therapies (CAR-T, CAR-NK, TCR-T, iPSC, Treg) from facilities in Gainesville, FL and Research Triangle Park, NC.

What Kincell Bio does

Kincell Bio is a U.S.-based cell therapy contract development and manufacturing organization (CDMO) founded in 2023 as a spinout of Inceptor Bio, headquartered in Gainesville, FL with a second facility in Research Triangle Park, NC. The company provides end-to-end CMC services to biotechnology and pharmaceutical companies developing engineered immune cell therapies, including process development, analytical development, GMP manufacturing, characterization and release testing, and tech transfer. Its modalities span CAR-T, CAR-NK, CAR-M, TCR-T, differentiated iPSC, and Treg programs across both autologous (one-batch, one-patient) and allogeneic (scalable, off-the-shelf) manufacturing models.

The platform is anchored in a two-site GMP manufacturing network with standardized process platforms enabling tech transfer from early-phase clinical supply in Gainesville to pivotal and commercial manufacturing in RTP. Kincell Bio sells directly to cell therapy sponsors through enterprise field sales, supported by content marketing, conference presence (CAR-TCR, Meeting on the Mesa, BIO, ASGCT, ISCT, CPHI), webinars, and LinkedIn thought leadership. Pricing is quote-based and negotiated per program; revenue is project-based with long-term, milestone-aligned contracts. The company has raised approximately $58 million in disclosed funding and is currently expanding the RTP facility to add two ISO 7 cleanrooms, additional QC, microbiology, and MSAT labs, expanded warehouse, and capacity for 100+ team members, with full operations targeted for Q3 2026. Leadership includes veterans from Catalent, Thermo Fisher, Brammer Bio, Resilience, Lyell, Fred Hutch, Pfizer, and Novartis, with Executive Chair Mark Bamforth having previously founded and exited three CDMOs.

Kincell Bio firmographics

Firmographics
Name
Kincell Bio
Legal name
Kincell Bio
Website
https://kincellbio.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
101–250 employees
Short description
Kincell Bio is a U.S.-based cell therapy CDMO providing CMC development, process development, analytical services, and GMP manufacturing for autologous and allogeneic immune cell therapies (CAR-T, CAR-NK, TCR-T, iPSC, Treg) from facilities in Gainesville, FL and Research Triangle Park, NC.
Ownership category
akta.pro rank

Kincell Bio industry classification

Industry
Product category
Cell Therapy CDMO Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Cell therapy CDMO
  • Contract manufacturing services
  • CMC development
  • GMP manufacturing
  • Process development

Where Kincell Bio is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Kincell Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing Services: Kincell Bio generates revenue through contract manufacturing and development services for cell therapy companies. Services include CMC roadmap development, process development, analytical development, GMP manufacturing, characterization and release testing, and tech transfer services. Revenue is project-based with long-term contracts typically aligned with client program milestones from early clinical through commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Kincell Bio product offering

Product offering

Core offering

Kincell Bio is a cell therapy Contract Development and Manufacturing Organization (CDMO) that provides integrated services across the full cell therapy product lifecycle for autologous and allogeneic programs including CAR-T, CAR-NK, CAR-M, TCR-T, iPSC, and Treg therapies. Services span CMC roadmap development, process and analytical development, GMP manufacturing, characterization and release testing, and tech transfer, delivered across two U.S. facilities in Gainesville, FL and Research Triangle Park, NC.

Product overview

Kincell Bio is a leading cell therapy CDMO (Contract Development and Manufacturing Organization) offering integrated services across the full cell therapy product lifecycle. The company's portfolio includes six core services: CMC Roadmap & Development, Early & Late Phase Process Development, Analytical Development & Methods, Clinical & Commercial GMP Manufacturing, Characterization & Release Testing, and Transfer In Playbook. These services support three development phases (Early-Phase Acceleration, Late-Phase Development, and Commercialization & Commercial Supply) and two therapy modalities (Autologous and Allogeneic Cell Therapies). Quality and regulatory support is provided through Quality Culture & Regulatory Support and PAI Readiness Program. The company operates two U.S. facilities (Gainesville, FL and Research Triangle Park, NC) providing end-to-end capabilities from concept through commercial supply.

Differentiator

Problem solved

Functional benefit

Products and services

  • CMC Roadmap & Development Strategic CMC roadmaps built for speed, rigor, and commercial success, helping innovators move cell therapies from concept to IND through structured CMC strategy, DoE-driven process development, and phase-appropriate analytics. Intended for cell therapy developers needing early-phase CMC planning.
  • Early & Late Phase Process Development Risk-based process development services from early feasibility through commercialization, integrating process optimization, control strategy strengthening, and scalable GMP execution. For cell therapy developers progressing from early feasibility to late-phase manufacturing.
  • Analytical Development & Methods Phase-appropriate platform methods, custom-developed and validated methods, in-process testing, tracking, and trending to ensure safety, potency, and consistency. For cell therapy developers needing identity, potency, and safety analytical data.
  • Clinical & Commercial GMP Manufacturing Reliable, PAI-ready GMP manufacturing from early clinical through commercial supply, ensuring consistent, patient-ready cell therapy production across two U.S. facilities (Gainesville, FL and Research Triangle Park, NC). For cell therapy sponsors needing clinical and commercial GMP supply.
  • Characterization & Release Testing Expert release testing and characterization ensuring safety and potency, building a foundation for quality and regulatory success through CQA-driven approaches and platform methods. For cell therapy developers requiring lot release and characterization support.
  • Transfer In Playbook Structured 8-point tech transfer playbook ensuring smooth program transitions using risk-based planning, cross-functional expertise, and phase-appropriate quality controls. For sponsors transferring cell therapy programs into Kincell's facilities.
  • Early-Phase Acceleration Risk-managed CMC roadmaps, DoE-driven process optimization, and phase-appropriate analytics balancing rapid IND readiness with long-term commercial strategy. For cell therapy sponsors preparing for IND filing and first-in-human studies.
  • Late-Phase Development Strengthened control strategies, process characterization, and comparability planning aligning analytical rigor, manufacturing scalability, and regulatory readiness for pivotal studies and BLA preparation. For sponsors advancing toward pivotal trials.
  • Commercialization & Commercial Supply Inspection-ready GMP operations, scalable manufacturing platforms, validated analytical control strategies, and supply chain resilience ensuring reliable, cost-conscious commercial supply. For sponsors of approved and late-stage cell therapies.
  • Autologous Cell Therapy CDMO Disciplined scale-out manufacturing for autologous therapies with one-batch, one-patient model, strict chain-of-identity controls, and scalable GMP production. For sponsors of patient-derived cell therapies such as CAR-T.
  • Allogeneic Cell Therapy CDMO Scalable allogeneic cell therapy manufacturing enabling off-the-shelf treatments with robust cell banking, scalable expansion platforms, and commercial-ready automation. For sponsors of donor-derived or renewable cell source therapies.
  • Quality Culture & Regulatory Support Embedding quality and regulatory readiness into every phase of cell therapy development with integrated CMC, analytics, and quality systems for inspection-ready operations. For sponsors needing integrated quality and regulatory support across development and manufacturing.
  • PAI Readiness Program PAI readiness built into everyday operations through regulatory mapping, phase-appropriate requirements, extensive operator training, data integrity, and analytical method readiness. For sponsors preparing for FDA pre-approval inspection.

Quantifiable outcome

  • Supporting clients advancing from late-stage clinical CMC development through commercialization and post-approval lifecycle management for both autologous and allogeneic cell therapy programs
  • +1 more outcomes

Companies that use Kincell Bio

Customer profile

Segments3 records

Ideal customer profiles3 records

Kincell Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Kincell Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • RegCellcoreStrategic or Co-development Partner · 10 February 2026Kincell Bio announced a partnership with RegCell, a biotechnology company developing Treg cell therapies for autoimmune diseases. Under the partnership, Kincell provides CMC development and GMP manufacturing support to accelerate RegCell's lead Treg program toward clinical trials, including process transfer, scalable manufacturing development, and clinical material supply for IND-enabling activities. RegCell's platform is based on epigenetically reprogrammed regulatory T cells developed by co-founder Professor Shimon Sakaguchi, the 2025 Nobel Prize laureate in Physiology or Medicine.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Kincell Bio competitors and assessment

Company assessment

Direct peers

  • Resilience: U.S.-based cell and gene therapy CDMO offering process development, GMP manufacturing, and analytical services across modalities including autologous and allogeneic therapies. Direct competitor for the same biotech customer base, with overlapping service lines and similar facility footprint scale.
  • WuXi Advanced Therapies Unit: Cell and gene therapy manufacturing services arm of WuXi AppTec/WuXi Biologics, offering process development, viral vectors, and cell therapy manufacturing. Direct competitor with substantial scale, though geopolitical and biosecurity policy risks have complicated its U.S. market position, opening room for Kincell.

Broad incumbents

  • Catalent (Novo Holdings): One of the largest global CDMOs with a dedicated cell and gene therapy business acquired by Novo Holdings in 2024. Offers a broad portfolio that includes cell therapy manufacturing, viral vectors, and biologics; competes with Kincell for cell therapy contracts but as part of a much larger service portfolio.
  • Lonza Cell & Gene Technologies: Global CDMO leader with extensive cell and gene therapy manufacturing capacity, including autologous and allogeneic platforms. Competes with Kincell for commercial-scale cell therapy supply contracts and represents one of the most likely strategic acquirers or partners for emerging cell therapy CDMOs.
  • Charles River Laboratories: Large CRO/CDMO offering cell therapy manufacturing, viral vector production, and integrated discovery-to-commercial services. Competes with Kincell primarily through its Cell & Gene Therapy CDMO segment and brings significantly broader scientific services and global reach.
  • AGC Biologics: Global CDMO providing cell therapy, viral vector, and biologics manufacturing services with facilities in the U.S. and Europe. Competes with Kincell for cell therapy developers seeking integrated CMC and GMP services at commercial scale.

Emerging players

  • Cellares: Cell therapy manufacturing technology company developing automated, closed-system Cell Shuttle platforms for autologous cell therapy production. Represents both a potential partner for Kincell's autologous work and a competitive threat if sponsors adopt in-house automated manufacturing.
  • Genezen: U.S.-based cell and gene therapy CDMO offering viral vector, cell therapy, and analytical services from its Indianapolis facility. Comparable size and growth stage to Kincell, serving a similar early-to-mid-stage biotech customer base.
  • Wheeler Bio: Emerging U.S. CDMO offering Portable CMC antibody and cell therapy process development and GMP services. Comparable scale and customer segment to Kincell; Kincell's Chief Commercial Officer previously launched Wheeler's Portable CMC service.
  • Matica Biotechnology: Cell and gene therapy CDMO offering viral vector and cell therapy manufacturing from a Texas facility. Comparable scale to Kincell with overlapping customer segments in early-to-mid-stage cell and gene therapy developers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Kincell Bio social profiles

Digital presence

Kincell Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kincell Bio leadership team

Management profile

Number of profiles

Profiles14 records

Kincell Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kincell Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kincell Bio

What does Kincell Bio do?

Kincell Bio is a cell therapy Contract Development and Manufacturing Organization (CDMO) that provides integrated services across the full cell therapy product lifecycle for autologous and allogeneic programs including CAR-T, CAR-NK, CAR-M, TCR-T, iPSC, and Treg therapies. Services span CMC roadmap development, process and analytical development, GMP manufacturing, characterization and release testing, and tech transfer, delivered across two U.S. facilities in Gainesville, FL and Research Triangle Park, NC.

Is Kincell Bio a public or private company?

Kincell Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kincell Bio founded?

Kincell Bio was founded in 2023. It employs 101 to 250 people.

Where is Kincell Bio based?

Kincell Bio is headquartered in Durham, United States, in the North America region.

How does Kincell Bio make money?

One revenue line is on record: contract Development and Manufacturing Services.

Who are Kincell Bio's main competitors?

Direct peers on record are Resilience and WuXi Advanced Therapies Unit. Broad incumbents are Catalent (Novo Holdings), Lonza Cell & Gene Technologies, Charles River Laboratories and AGC Biologics. Emerging players are Cellares, Genezen, Wheeler Bio and Matica Biotechnology.

Does Kincell Bio have an API?

No public API is recorded for Kincell Bio.

What industry is Kincell Bio in?

Kincell Bio's product category is Cell Therapy CDMO Services. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanMarker Therapeutics: Kincellis partner has 140,000 sq. ft.Marker Therapeutics highlighted expanded manufacturing support from its CDMO partner Kincellis, formed by combining Cellipont Bioservices and Kincell Bio. The combined CDMO has about 140,000 square feet of infrastructure and 16 GMP suites across three U.S. locations, strengthening MT-601 manufacturing as it advances toward later-stage trials.BioSpaceKincell Bio and Cellipont Bioservices Merge to Form Kincellis Advanced TherapiesKincell Bio and Cellipont Bioservices merged to form Kincellis Advanced Therapies, a U.S.-based CDMO for cell therapies. The combined company has released over 150 GMP batches and supports 10 IND filings this year. The merger was led by NewSpring Capital with support from existing investors and J.P. Morgan.citybizKincell Bio and Cellipont Merge to Form Advanced Therapies CDMO KincellisKincell Bio and Cellipont Bioservices merged to form Kincellis Advanced Therapies, a U.S.-based CDMO with 140,000 square feet of infrastructure. Financial terms were not disclosed, with equity led by NewSpring Capital and J.P. Morgan providing debt. The combined company supports autologous and allogeneic therapies across three U.S. facilities.CellipontKincell Bio and Cellipont Bioservices Merge to Form Kincellis Advanced Therapies. Combination creates a scaled U.S. advanced therapies CDMO with broader technical expertise and capabilities from earlyKincell Bio and Cellipont Bioservices merged to form Kincellis Advanced Therapies, a U.S. cell therapy CDMO. The combined company operates 140,000 square feet of facilities and has released over 150 GMP batches, supporting 10 IND filings this year. Equity financing was led by NewSpring Capital with support from existing investors.KincellbioKincell Bio and Cellipont Bioservices Merge to Form Kincellis Advanced TherapiesKincell Bio and Cellipont Bioservices merged to form Kincellis Advanced Therapies, a U.S. CDMO for cell therapies. The combined company operates 140,000 square feet across three sites and has released over 150 GMP batches, supporting 10 IND filings this year.ContractpharmaBuilding Cell Therapy the Right WayKincell Bio executives Roger Herr and Patrick Kellish argue that early investment in robust analytical methods is critical for successful cell therapy development, emphasizing that decisions made at the earliest stages directly impact scalability and commercialization feasibility. The authors recommend a design-of-experiment (DoE) approach to accelerate assay development while reducing time and cost, along with phase-appropriate stage gates to mitigate quality and compliance risks. The article promotes Kincell Bio's science-first analytical development services as a means for cell therapy developers to navigate regulatory expectations and advance programs toward commercialization.BioSpaceKincell Bio Announces Strategic Expansion of Research Triangle Park Facility to Support Late-Stage and Commercial Cell Therapy Manufacturing ProgramsKincell Bio announced a multi-million dollar strategic investment to expand its Research Triangle Park, North Carolina facility, adding two ISO 7 cleanroom suites, additional laboratories for quality control, process development, and microbiology testing, expanded GMP warehouse space, and workspaces for over 100 employees. The expansion is designed to support clients advancing from late-stage clinical CMC development through commercialization and post-approval lifecycle management for both autologous and allogeneic cell therapy programs. The facility is projected to be fully operational by the end of Q3 2026, and the company is simultaneously investing in Veeva quality management and ERP systems to support commercial-stage operations.Business Wire BlogKincell Bio Announces Strategic Expansion of Research Triangle Park Facility to Support Late-Stage and Commercial Cell Therapy Manufacturing ProgramsKincell Bio announced a strategic investment to expand its Research Triangle Park, North Carolina facility, adding two ISO 7 cleanroom suites along with additional QC, microbiology, and MSAT/ASAT laboratories, expanded GMP warehouse space, and administrative workspaces for over 100 team members. The expansion is designed to support clients advancing autologous and allogeneic cell therapy programs from late-stage clinical development through commercialization, with the facility projected to be fully operational by the end of Q3 2026. The company is also investing in its Veeva quality management system and enterprise ERP system to support commercial-stage operations.BioSpaceKincell Bio Announces Partnership with RegCell to Advance Treg Cell Therapies into Clinical Trials for Autoimmune DiseasesKincell Bio, a U.S. cell therapy contract development and manufacturing organization (CDMO), announced a new collaboration with biotechnology company RegCell to advance RegCell's lead regulatory T cell (Treg) therapy program toward clinical trials for autoimmune diseases. Under the partnership, Kincell Bio will provide comprehensive CMC development and GMP manufacturing support, including process transfer, scalable manufacturing optimization, and clinical material supply for IND-enabling activities. RegCell's platform, founded on the work of Nobel laureate Professor Shimon Sakaguchi, converts disease-driving T cells into lineage-stable Tregs without requiring gene editing or viral DNA reagents, potentially reducing manufacturing complexity.PharmiWeb.comKincell Bio Announces Partnership with RegCell to Advance Treg Cell Therapies into Clinical Trials for Autoimmune DiseasesKincell Bio, a U.S. cell therapy contract development and manufacturing organization (CDMO), announced a collaboration with RegCell, a biotechnology company developing Treg cell therapies for autoimmune diseases. Under the partnership, Kincell Bio will provide CMC development and GMP manufacturing support to accelerate RegCell's lead Treg program toward clinical trials, including process transfer, scalable manufacturing development, and clinical material supply for IND-enabling activities. RegCell's platform is based on epigenetically reprogrammed regulatory T cells developed by co-founder Professor Shimon Sakaguchi, the 2025 Nobel Prize laureate in Physiology or Medicine, and does not require gene editing or viral DNA reagents, simplifying manufacturing complexity.